Programs & products

Innate Pharma S.A. announced that a set of pharmacological data, from Research to clinical Phase II, of its drug candidate IPH 1101 was presented at the "American Society of Clinical Oncology" annual...

Innate Pharma S.A. today announced two additional clinical trials for its IPH 1101 drug candidate, including the first Innate's trial outside oncology.

Eric Vivier's team at the marseille-luminy Immunology Centre and Innate Pharma researchers announced the development of a new animal model dedicated to studying NK cell activity.

Innate Pharma SA announced today that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans.

Innate Pharma SA announced today the commercial launch by its partner, Clinical Data Inc. (NASDAQ: CLDA) of PGxPredict:RITUXIMAB, a pharmacogenetic test that should help physicians to predict the...

Innate Pharma announces worldwide exclusive license with Clinical Data Inc. for the development of a predictive test for response to monoclonal antibody treatment.

Innate pharma has selected a new immuno-modulatory compound for its T gamma-delta platform, IPH 1201. Entering its pre-clinical and pharmaceutical development, IPH 1201 is intended to be developed in...

Innate pharma presents encouraging data on its immunomodulatory product candidate IPH 1101 with final results from phase I clinical trial in solid tumours (Trial D004-101).

Innate Pharma strengthens its platform in the pharmacology of Toll-like-receptors (TLR) with assets licensed from US-based global pharmaceutical company Schering-Plough Corporation and advanced R&D...

Innate pharma presents encouraging data on IPH 1101 at the American society of clinical oncology's 2006 annual meeting and moves its drug candidate into phase II kidney cancer clinical trial.